{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:27:56Z","timestamp":1790756876284,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"am","delay-in-days":315,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajo.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T09:20:03Z","timestamp":1644744003000},"page":"173-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4554-1922","authenticated-orcid":false,"given":"Georgina","family":"Maalouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4804-4611","authenticated-orcid":false,"given":"Ana\u00efs","family":"Andrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2484-7009","authenticated-orcid":false,"given":"Philip","family":"Bielefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Gueudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sen\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherif","family":"Titah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-6086","authenticated-orcid":false,"given":"Thomas","family":"Moulinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9621-3400","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8640-4580","authenticated-orcid":false,"given":"Damien","family":"S\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Desbois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-556X","authenticated-orcid":false,"given":"Carolla El","family":"Chamieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0660-1264","authenticated-orcid":false,"given":"Lucie","family":"Biard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2022.02.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.695904","article-title":"Epidemiology and risk factors in non-infectious uveitis: a systematic review","volume":"8","author":"Joltikov","year":"2021","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.ajo.2022.02.002_bib0002","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ophtha.2015.10.028","article-title":"Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"123","author":"Dick","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.002_bib0003","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2017.02.028","article-title":"Tomkins-Netzer O. Clinical outcome of retinal vasculitis and predictors for prognosis of ischemic retinal vasculitis","volume":"177","author":"Sharief","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.02.002_bib0004","article-title":"Long-term efficacy and tolerability of TNF\u03b1 inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study","author":"Sharma","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2022.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"D\u00edaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.002_bib0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.02.003","article-title":"The immunopathogenesis of chronic and relapsing autoimmune uveitis-lessons from experimental rat models","volume":"65","author":"Diedrichs-M\u00f6hring","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.ajo.2022.02.002_bib0007","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2165\/00003495-200565040-00005","article-title":"Management of sight-threatening uveitis: new therapeutic options","volume":"65","author":"Becker","year":"2005","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ajo.2022.02.002_bib0008","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ajo.2022.02.002_bib0009","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"issue":"10050","key":"10.1016\/j.ajo.2022.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ajo.2022.02.002_bib0011","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ajo.2022.02.002_bib0012","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14712598.2019.1595578","article-title":"Expert opinion on the use of biological therapy in non-infectious uveitis","volume":"19","author":"Touhami","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.ajo.2022.02.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti\u2013tumor necrosis factor biological agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2022.02.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ajo.2022.02.002_bib0015","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/jcm9113599","article-title":"Biotherapies in uveitis","volume":"9","author":"Leclercq","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ajo.2022.02.002_bib0016","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/art.39667","article-title":"Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network","volume":"68","author":"Vallet","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ajo.2022.02.002_bib0017","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ophtha.2019.08.031","article-title":"Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"127","author":"Al-Janabi","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2022.02.002_bib0018","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2022.02.002_bib0019","article-title":"The efficacy of adalimumab as an initial treatment in patients with Beh\u00e7et's retinal vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.ajo.2022.02.002_bib0020","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s10067-018-4133-z","article-title":"Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.ajo.2022.02.002_bib0021","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41433-019-0481-4","article-title":"Cochrane corner: why we still don't know whether anti-TNF biological therapies impact uveitic macular oedema","volume":"33","author":"Braithwaite","year":"2019","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.ajo.2022.02.002_bib0022","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","article-title":"Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et's syndrome","volume":"28","author":"Silvestri","year":"2020","journal-title":"Inflammopharmacology"},{"issue":"12","key":"10.1016\/j.ajo.2022.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1136\/bjophthalmol-2017-311234","article-title":"Adalimumab for the treatment of refractory active and inactive non-infectious uveitis","volume":"102","author":"Lee","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2022.02.002_bib0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","article-title":"Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients","volume":"38","author":"Fabiani","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.ajo.2022.02.002_bib0025","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et's disease: national multicenter study of 177 cases","volume":"71","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ajo.2022.02.002_bib0026","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2022.02.002_bib0027","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.revmed.2018.02.022","article-title":"Les manifestations oculaires de la maladie de Beh\u00e7et","volume":"39","author":"Desbois","year":"2018","journal-title":"Rev M\u00e9decine Interne"},{"issue":"10","key":"10.1016\/j.ajo.2022.02.002_bib0028","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.ophtha.2014.04.042","article-title":"Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Beh\u00e7et's disease","volume":"121","author":"Takeuchi","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2022.02.002_bib0029","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et's disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ajo.2022.02.002_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422000496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939422000496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:50:08Z","timestamp":1757598608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939422000496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":30,"alternative-id":["S0002939422000496"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2022.02.002","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}